Case Summary: Sindell v. Abbott Laboratories 1980
By Priya Pillai

In short
Explore the landmark Sindell v. Abbott Laboratories 1980 case, pivotal in establishing market share liability in product liability law. Learn more now!
In this brief
Background: DES and the Identification Problem
Between 1947 and 1971, pharmaceutical companies across the United States manufactured and marketed diethylstilbestrol (DES) — a synthetic estrogen — prescribed to pregnant women to prevent miscarriages and pregnancy complications. Approximately 200 manufacturers produced DES from an identical generic formula, selling it under dozens of brand names.
DES was later found to be entirely ineffective at preventing miscarriages. Worse, daughters born to women who took DES during pregnancy developed a rare and aggressive cancer — clear-cell adenocarcinoma of the vagina and cervix — at unusually high rates, typically manifesting a decade or more after birth.

When DES daughters began filing suit in the 1970s, they confronted an impossible evidentiary wall: because DES was chemically fungible (all pills identical), because brand names were rarely recorded, and because decades had passed, plaintiffs could not identify which of the ~200 manufacturers had made the specific pill their mother swallowed. Under traditional tort law, an inability to prove which defendant caused the harm meant the claim failed.
Key Facts
| Detail | |
|---|---|
| Court | Supreme Court of California |
| Citation | 26 Cal.3d 588; 607 P.2d 924 (1980) |
| Decided | 20 March 1980 |
| Plaintiff | Judith Sindell (DES daughter; alleged a malignant bladder tumour, removed by surgery, and adenosis) |
| Defendants | Eleven drug companies were sued; five were respondents on appeal: Abbott Laboratories, Eli Lilly, E.R. Squibb & Sons, Upjohn and Rexall |
| Drug at issue | Diethylstilbestrol (DES), authorised as a miscarriage preventative in 1947; in 1971 the FDA ordered the defendants to stop marketing it for that purpose |
| Core problem | Plaintiff could not identify which of ~200 manufacturers made the DES her mother took |
| Majority | Justice Stanley Mosk, with Bird CJ, Newman J and White J (4-3) |
| Dissent | Justice Frank Richardson, with Clark J and Manuel J |
| Doctrine created | Market share liability |
Prior Theories and Why They Failed
Judith Sindell's complaint pleaded negligence, strict liability, breach of warranty, fraud, misbranding, conspiracy and "lack of consent". The trial court sustained the defendants' demurrers because she could not identify the manufacturer, and dismissed the action. On appeal, the California Supreme Court considered three existing routes around the identification problem and held that none applied as previously interpreted:
- Alternative liability (Summers v. Tice, 1948): shifts the burden of proof where all the possible wrongdoers are before the court. Sindell had joined only five of about 200 makers, so there was a real chance that none of them made the drug. The court did not accept the defendants' other argument, that the rule requires defendants to have better access to the evidence.
- Concert of action: requires a common plan or tacit understanding to commit a tort. Relying on each other's testing and marketing methods was only parallel or imitative conduct.
- Industry-wide ("enterprise") liability (Hall v. E.I. Du Pont, 1972): that case involved six blasting-cap makers, virtually the whole US industry, who had delegated safety functions to a trade association. DES had at least 200 makers, no such delegation was alleged, and the FDA closely regulated drug standards.
The court then adopted a fourth basis, an extension of Summers, and reversed the judgments of dismissal. A parallel case brought by Maureen Rogers was consolidated on appeal.
The Majority: Market Share Liability (Justice Mosk)

Justice Mosk, writing for a 4-3 majority, held that a plaintiff who cannot identify which DES manufacturer supplied the drug that injured her may nonetheless sue, provided she joins defendants who together represent a substantial share of the DES market at the relevant time.
How Market Share Liability Works
- The plaintiff joins the manufacturers of a substantial share of the DES her mother might have taken, measured by DES sold to prevent miscarriage. The court set no figure: it noted the 75 to 80 percent suggested in a law review comment, but held only that a "substantial percentage" is required.
- The burden then shifts. Each defendant may escape by proving it could not have made the product that injured the plaintiff. The court's example was a company that did not make DES until after she was born. Joined defendants may also cross-complain against other manufacturers.
- A defendant that cannot exculpate itself is liable for the proportion of the judgment represented by its share of the appropriate market.
- Sindell did not decide whether that liability is joint or several. In Brown v. Superior Court, 44 Cal.3d 1049 (1988), the court held it several only, so a plaintiff who does not join the whole market recovers less than 100%.
Policy Rationale
The court gave these reasons for the new doctrine:
- Innocent plaintiff, negligent defendants. As in Summers, as between the two the defendants should bear the cost of the injury.
- The gap in proof. The plaintiff was not at fault, and marketing a drug with effects delayed for many years played a significant role in making the proof unavailable.
- Defendants are better able to bear the loss. Manufacturers can insure the risk and distribute it as a cost of doing business.
- Product safety. The manufacturer is best placed to discover defects and warn of them, so liability gives an incentive to safety.
- Proportionality. Over the run of cases, each maker's liability would approximate its responsibility for the injuries caused by its own products.
The court described this as a modification of the Summers rule, warranted where all the defendants produced a drug from an identical formula and the plaintiff, through no fault of her own, cannot identify the manufacturer.
The Dissent: Justice Richardson
Justice Richardson, joined by Justices Clark and Manuel, dissented on causation and policy grounds:
- Causation deficit. Tort liability has always required proof that this defendant harmed this plaintiff. Under the new rule a defendant could be liable even though it was mathematically more likely than not that it played no part in the injury.
- Uneven burden. Only five of about 200 makers had been joined, "substantial" was left undefined, and those sued in California could end up bearing effective joint responsibility for the whole injury.
- Deep pockets and drug research. A defendant's wealth is no basis for liability, and imposing this liability a generation after FDA-approved use would inhibit the dissemination of new drugs.
- Legislature's role. The policy decision to introduce market share liability should rest with the legislature, not the courts.
Richardson J's dissent has been influential: courts that declined to adopt the doctrine, such as the Illinois Supreme Court in Smith v. Eli Lilly & Co., raised the same concerns.
Adoption, Modification, and Rejection by Other Courts

| Jurisdiction | Case | Outcome |
|---|---|---|
| New York | Hymowitz v. Eli Lilly & Co., 73 N.Y.2d 487 (1989) | Adopted, but used a national market share; a maker in the pregnancy-use market cannot escape by showing it did not cause this plaintiff's injury |
| Washington | Martin v. Abbott Laboratories, 102 Wn.2d 581 (1984) | Adopted a variant, "market share alternative liability", after rejecting Sindell's version |
| Wisconsin | Collins v. Eli Lilly & Co., 116 Wis.2d 166 (1984) | Adopted a risk-contribution variant, extended to lead pigment in Thomas v. Mallett, 2005 WI 129. A 2013 statute (Wis. Stat. § 895.046) tried to extinguish the theory; Gibson v. American Cyanamid Co., 760 F.3d 600 (7th Cir. 2014), held it could not apply retroactively to pending cases and that the theory survives federal due process |
| Florida | Conley v. Boyle Drug Co., 570 So.2d 275 (1990) | Adopted Washington's theory, if the plaintiff first makes a genuine attempt to identify the maker |
| Hawaii | Smith v. Cutter Biological, Inc., 72 Haw. 416, 823 P.2d 717 (1991) | Adopted an alternative market-share theory for a blood-clotting product (Factor VIII), not DES |
| Pennsylvania | Skipworth v. Lead Industries Ass'n, 690 A.2d 169 (1997) | Declined to apply it to lead paint, which is not fungible and was sold over about a century |
| Texas | Gaulding v. Celotex Corp., 772 S.W.2d 66 (1989) | Refused to apply it to asbestos board on the facts, without approving or disapproving the theory |
| Illinois, Ohio, Missouri, Iowa | Smith v. Eli Lilly & Co., 137 Ill.2d 222 (1990); Sutowski v. Eli Lilly & Co., 82 Ohio St.3d 347 (1998); Zafft v. Eli Lilly & Co., 676 S.W.2d 241 (Mo. 1984); Mulcahy v. Eli Lilly & Co., 386 N.W.2d 67 (Iowa 1986) | Rejected market share liability in DES cases |
Only a minority of U.S. states have adopted any form of market share liability. California, New York, Washington, Wisconsin, Florida and Hawaii are the main examples, each with its own modifications.
Significance and Legacy
Sindell is foundational to modern products liability for two reasons:
- It solved the fungibility problem. For the first time, courts had a workable framework for cases where a product's generic nature makes specific identification impossible.
- It reconceived the causation requirement. Rather than requiring proof that defendant X caused plaintiff Y's specific harm, the court allowed probabilistic, market-level causation — a conceptual shift that influenced academic tort scholarship for decades.
The doctrine has been raised (with mixed results) in asbestos cases, lead-paint cases, and MTBE groundwater contamination litigation — wherever the identity of the specific tortfeasor is unknowable because many identical products were placed into commerce.

About the author
Priya Pillai is the founder of LegalFly and has taught law for 9 years. She explains case law and legal concepts on the LegalFly YouTube channel.
